Insider Transactions in Q1 2024 at Perrigo CO PLC (PRGO)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 07
2024
|
Grainne Quinn EVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,170
-5.26%
|
$33,930
$29.69 P/Share
|
|
Mar 07
2024
|
Grainne Quinn EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,249
+9.18%
|
$65,221
$29.69 P/Share
|
|
Mar 07
2024
|
Robert Willis EVP & CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,125
-3.45%
|
$32,625
$29.69 P/Share
|
|
Mar 07
2024
|
Robert Willis EVP & CHRO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,163
+6.22%
|
$62,727
$29.69 P/Share
|
|
Mar 07
2024
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
886
-2.57%
|
$25,694
$29.69 P/Share
|
|
Mar 07
2024
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,942
+7.87%
|
$85,318
$29.69 P/Share
|
|
Mar 07
2024
|
Alison Ives EVP & Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
526
-2.84%
|
$15,254
$29.69 P/Share
|
|
Mar 07
2024
|
Alison Ives EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,746
+8.61%
|
$50,634
$29.69 P/Share
|
|
Mar 07
2024
|
Svend Andersen EVP & President CHCI |
BUY
Exercise of conversion of derivative security
|
Direct |
5,468
+5.14%
|
$158,572
$29.69 P/Share
|
|
Mar 06
2024
|
Grainne Quinn EVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
915
-4.38%
|
$25,620
$28.09 P/Share
|
|
Mar 06
2024
|
Grainne Quinn EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,759
+7.76%
|
$49,252
$28.09 P/Share
|
|
Mar 06
2024
|
Robert Willis EVP & CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
915
-2.92%
|
$25,620
$28.09 P/Share
|
|
Mar 06
2024
|
Robert Willis EVP & CHRO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,759
+5.31%
|
$49,252
$28.09 P/Share
|
|
Mar 06
2024
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
693
-2.15%
|
$19,404
$28.09 P/Share
|
|
Mar 06
2024
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,300
+6.67%
|
$64,400
$28.09 P/Share
|
|
Mar 06
2024
|
Kyle Hanson EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,147
-9.34%
|
$32,116
$28.09 P/Share
|
|
Mar 06
2024
|
Kyle Hanson EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
3,518
+22.26%
|
$98,504
$28.09 P/Share
|
|
Mar 06
2024
|
Thomas Farrington EVP and CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
696
-6.11%
|
$19,488
$28.09 P/Share
|
|
Mar 06
2024
|
Thomas Farrington EVP and CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,881
+14.17%
|
$52,668
$28.09 P/Share
|
|
Mar 06
2024
|
Eduardo Guarita Bezerra EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,267
-9.53%
|
$35,476
$28.09 P/Share
|
|
Mar 06
2024
|
Eduardo Guarita Bezerra EVP & Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,870
+26.81%
|
$136,360
$28.09 P/Share
|
|
Mar 06
2024
|
Alison Ives EVP & Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
612
-3.52%
|
$17,136
$28.09 P/Share
|
|
Mar 06
2024
|
Alison Ives EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,030
+10.45%
|
$56,840
$28.09 P/Share
|
|
Mar 06
2024
|
Svend Andersen EVP & President CHCI |
BUY
Exercise of conversion of derivative security
|
Direct |
3,788
+3.82%
|
$106,064
$28.09 P/Share
|
|
Mar 05
2024
|
Alison Ives EVP & Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,262
-4.14%
|
$34,074
$27.26 P/Share
|
|
Mar 05
2024
|
Alison Ives EVP & Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
2,490
+13.38%
|
$67,230
$27.26 P/Share
|
|
Mar 05
2024
|
Alison Ives EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,698
+10.72%
|
$45,846
$27.26 P/Share
|
|
Mar 05
2024
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,178
-6.71%
|
$112,806
$27.26 P/Share
|
|
Mar 05
2024
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
BUY
Grant, award, or other acquisition
|
Direct |
11,806
+26.09%
|
$318,762
$27.26 P/Share
|
|
Mar 05
2024
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,071
+8.51%
|
$55,917
$27.26 P/Share
|
|
Mar 05
2024
|
Robert Willis EVP & CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,458
-6.92%
|
$120,366
$27.26 P/Share
|
|
Mar 05
2024
|
Robert Willis EVP & CHRO |
BUY
Grant, award, or other acquisition
|
Direct |
7,291
+17.93%
|
$196,857
$27.26 P/Share
|
|
Mar 05
2024
|
Robert Willis EVP & CHRO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,279
+4.56%
|
$34,533
$27.26 P/Share
|
|
Mar 05
2024
|
Grainne Quinn EVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,519
-12.48%
|
$149,013
$27.26 P/Share
|
|
Mar 05
2024
|
Grainne Quinn EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,028
+27.46%
|
$243,756
$27.26 P/Share
|
|
Mar 05
2024
|
Grainne Quinn EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,583
+9.19%
|
$42,741
$27.26 P/Share
|
|
Mar 05
2024
|
Thomas Farrington EVP and CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,660
-21.83%
|
$125,820
$27.26 P/Share
|
|
Mar 05
2024
|
Thomas Farrington EVP and CIO |
BUY
Grant, award, or other acquisition
|
Direct |
9,652
+41.62%
|
$260,604
$27.26 P/Share
|
|
Mar 05
2024
|
Thomas Farrington EVP and CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,693
+27.27%
|
$45,711
$27.26 P/Share
|
|
Mar 05
2024
|
Svend Andersen EVP & President CHCI |
BUY
Grant, award, or other acquisition
|
Direct |
19,445
+17.51%
|
$525,015
$27.26 P/Share
|
|
Mar 05
2024
|
Svend Andersen EVP & President CHCI |
BUY
Exercise of conversion of derivative security
|
Direct |
3,411
+4.51%
|
$92,097
$27.26 P/Share
|
|
Mar 01
2024
|
Robert Willis EVP & CHRO |
BUY
Open market or private purchase
|
Direct |
371
+1.44%
|
$9,646
$26.3 P/Share
|
|
Feb 29
2024
|
Alison Ives EVP & Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
1,545
+11.04%
|
$40,170
$26.44 P/Share
|
|
Feb 29
2024
|
Robert Willis EVP & CHRO |
BUY
Open market or private purchase
|
Direct |
6,000
+19.29%
|
$150,000
$25.87 P/Share
|
|
Feb 29
2024
|
Patrick Lockwood Taylor CEO |
BUY
Open market or private purchase
|
Direct |
9,500
+31.67%
|
$247,000
$26.54 P/Share
|